AI Engines For more Details: Perplexity Kagi Labs You
Anesthesia: Tiletamine hydrochloride is used for general anesthesia in animals, particularly in cats and non-human primates. It produces a rapid onset of anesthesia and maintains anesthesia for a relatively short duration, making it suitable for procedures of varying lengths.
Analgesia: Tiletamine hydrochloride provides analgesia (pain relief) along with anesthesia, which can be beneficial for surgical procedures that may cause pain or discomfort.
Sedation: Tiletamine hydrochloride can also be used for sedation in veterinary medicine. It produces a calming effect and may be administered to facilitate handling, restraint, or minor procedures in animals.
Muscle Relaxation: Tiletamine hydrochloride has muscle relaxant properties, which can be advantageous during surgical procedures by reducing muscle tone and preventing involuntary movements.
Rapid Onset and Recovery: One of the advantages of tiletamine hydrochloride is its rapid onset of action, allowing for quick induction of anesthesia or sedation. Additionally, animals typically recover from anesthesia relatively quickly after discontinuation of tiletamine administration.
Combination Therapy: Tiletamine hydrochloride is often combined with zolazepam, a benzodiazepine derivative, to form a combination drug known as Zoletil or Telazol. This combination enhances the anesthetic effects and provides balanced anesthesia, combining the sedative and muscle relaxant properties of both drugs.
Respiratory Depression: Tiletamine hydrochloride, like other anesthetic agents, can cause respiratory depression in animals. Careful monitoring of respiratory rate and effort is essential during anesthesia to prevent respiratory complications.
Cardiovascular Effects: Tiletamine hydrochloride may have cardiovascular effects, including alterations in heart rate and blood pressure. Monitoring of cardiac function is recommended during anesthesia, especially in animals with pre-existing cardiovascular conditions.
Recovery Considerations: After administration of tiletamine hydrochloride, animals may experience disorientation, ataxia (loss of coordination), and muscle tremors during the recovery period. Providing a quiet and safe environment for recovery is important to minimize stress and prevent injury.
Safety and Handling: Tiletamine hydrochloride is a potent anesthetic agent and should be handled with care to prevent accidental exposure or ingestion. Proper storage and disposal procedures should be followed to ensure safety.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.3 | 0.3 | 3.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.3 | 1.33 |
| Allergies | 0.7 | 0.7 | |
| Allergy to milk products | 0.4 | -0.4 | |
| Alopecia (Hair Loss) | 0 | 0 | |
| Alzheimer's disease | 1 | 1.2 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.7 | 1.1 | -0.57 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.3 | 0.33 |
| Asthma | 1.6 | 0.8 | 1 |
| Atherosclerosis | 0.6 | -0.6 | |
| Atrial fibrillation | 1 | 0.7 | 0.43 |
| Autism | 1.9 | 2 | -0.05 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1 | 0.8 | 0.25 |
| Brain Trauma | 0.3 | 0.5 | -0.67 |
| Carcinoma | 1.3 | 0.4 | 2.25 |
| Celiac Disease | 0.4 | 1 | -1.5 |
| Cerebral Palsy | 0.3 | 0.5 | -0.67 |
| Chronic Fatigue Syndrome | 0.9 | 0.4 | 1.25 |
| Chronic Kidney Disease | 0.7 | 1.1 | -0.57 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 1.1 | -1.75 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1.3 | 0.8 | 0.63 |
| Colorectal Cancer | 1.4 | 0.5 | 1.8 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.3 | 0.5 | -0.67 |
| COVID-19 | 1.4 | 1.4 | 0 |
| Crohn's Disease | 1.9 | 1.4 | 0.36 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.5 | 0.8 | -0.6 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 2.5 | 1.6 | 0.56 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.4 | -0.33 |
| Endometriosis | 0.7 | 0.8 | -0.14 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.3 | 0.4 | -0.33 |
| Fibromyalgia | 1.3 | 1.3 | |
| Functional constipation / chronic idiopathic constipation | 1.1 | 1 | 0.1 |
| gallstone disease (gsd) | 0.4 | 0.5 | -0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 0.6 | 0.8 | -0.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.4 | 0.8 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.5 | 0.6 | -0.2 |
| Heart Failure | 0.9 | 0.5 | 0.8 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.1 | 0.4 | -3 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1 | 1.3 | -0.3 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 1 | 0.7 | 0.43 |
| Inflammatory Bowel Disease | 1.5 | 1.3 | 0.15 |
| Insomnia | 0.4 | 1.1 | -1.75 |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.8 | 1.6 | -1 |
| ischemic stroke | 0.7 | 0.5 | 0.4 |
| Liver Cirrhosis | 1.9 | 1.1 | 0.73 |
| Long COVID | 1.3 | 1.7 | -0.31 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.9 | 0 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 1.9 | 1.6 | 0.19 |
| Mood Disorders | 2.5 | 1.8 | 0.39 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 1.8 | 1.4 | 0.29 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 1.3 | -3.33 |
| Neuropathy (all types) | 0.6 | 1 | -0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.8 | 0.38 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 1.9 | 1.9 | 0 |
| obsessive-compulsive disorder | 1 | 0.3 | 2.33 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.8 | 0.3 | 1.67 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1.9 | 1.2 | 0.58 |
| Polycystic ovary syndrome | 1.3 | 1.1 | 0.18 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.7 | 0.5 | 0.4 |
| Psoriasis | 0.3 | 1 | -2.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 0.5 | 3.2 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.6 | 1.3 | 0.23 |
| scoliosis | 0.4 | -0.4 | |
| Sjögren syndrome | 0.7 | 0.4 | 0.75 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1 | 1.3 | -0.3 |
| Systemic Lupus Erythematosus | 1.3 | 0.9 | 0.44 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.6 | 1.1 | -0.83 |
| Type 2 Diabetes | 1.8 | 1.3 | 0.38 |
| Ulcerative colitis | 1 | 1.3 | -0.3 |
| Unhealthy Ageing | 0.9 | 1 | -0.11 |
| Vitiligo | 1 | 0.4 | 1.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
